Mechanical circulatory support and heart transplantation for treatment of chronic heart failure

Czech version

Authors: P. Fila ^1,2; H. Bedáňová ^1,2; V. Horváth ^1,2; J. Ondrášek ¹; P. Piler ^1,2; P. Němec ^1,2
Authors‘ workplace: Centrum kardiovaskulární a transplantační chirurgie, Brno ¹; Mezinárodní centrum klinického výzkumu, FN u sv. Anny v Brně ²
Published in: Kardiol Rev Int Med 2014, 16(2): 109-115
Category: Cardiology Review

Overview

Heart transplantation is the gold standard for patients with end‑stage heart failure. The available donor supply limits the number of cardiac transplants. Transplant centres need to provide alternative therapy for these patients with heart failure. The mechanical circulatory support systems are used as a bridge to transplantation in heart transplant candidates (long‑term support). This review describes the current status of heart transplantation and long‑term mechanical circulatory support devices for treatment of chronic heart failure.

Keywords:
chronic heart failure – mechanical circulatory support – heart transplantation

Sources

1. Spinar J, Vitovec J, Hradec J et al. Czech Society of Cardiology guidelines for the diagnosis and treatment of chronic heart failure 2011. Cor et Vasa 2012; 54: e113– e134. doi: 10.1016/ j.crvasa.2012.05.001.

2. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787– 1847. doi: 10.1093/ eurheartj/ ehs104.

3. Stewart S, Ekman I, Ekman T et al. Population impact of heart failure and the most common forms of cancer: a study of 1 162 309 hospital cases in Sweden (1988 to 2004). Circ Cardiovasc Qual Outcomes 2010; 3: 573– 580. doi: 10.1161/ CIRCOUTCOMES.110.957571.

4. Jhund PS, Macintyre K, Simpson CR et al. Long‑term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: a population study of 5.1 million people. Circulation 2009; 119: 515– 523. doi: 10.1161/ CIRCULATIONAHA.108.812172

5. Lewis EF, Johnson PA, Johnson W et al. Preferences for quality of life or survival expressed by patients with heart failure. J Heart Lung Transplant 2001; 20: 1016– 1024. doi: 10.1016/ S1053– 2498(01)00298– 4.

6. Stewart S, MacIntyre K, Hole DJ et al. More ‘malignant’ than cancer? Five‑year survival following a first admission for heart failure. Eur J Heart Fail 2001; 3: 315– 322. doi: 10.1016/ S1388– 9842(00)00141– 0.

7. Koordinační středisko transplantací: Statistiky 2014. Dostupné z: http:/ / www.kst.cz/ web/ ?cat=4.

8. Vasku J, Cerny J, Dostal M et al. Recent efforts in artificial heart research in Czechoslovakia. ASAIO Trans 1989, 35: 805– 811.

9. Elhenawy AM, Algarni KD, Rodger M el al. Mechanical circulatory support as a bridge to transplant candidacy. J Card Surg 2011; 26: 542– 547. doi: 10.1111/ j.1540- 8191.2011.01310.x.

10. Kirklin JK, Naftel DC, Kormos RL et al. Fifth INTERMACS annual report: risk factor analysis from more than 6,000 mechanical circulatory support patients. J Heart Lung Transplant 2013, 32: 141– 156. doi: 10.1016/ j.healun.2012.12.004.

11. Schaffer JM, Allen JG, Weiss ES et al. Evaluation of risk indices in continuous‑ flow left ventricular assist device patients. Ann Thorac Surg 2009; 88: 1889– 1896. doi: 10.1016/ j.athoracsur.2009.08.011.

12. Acker MA, Pagani FD, Stough WG et al. Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States. Circ Heart Fail, 2013, 6: e1– e11. doi: 10.1161/ HHF.0b013e318279f6b5.

13. Rojas SV, Avsar M, Hanke JS et al. Minimally‑ Invasive Implantation of Left Ventricular Assist Devices Improves the Operative Outcome in Adult Patients with Severe Heart Failure. J Heart Lung Transplant 2013; 32: S142. doi: 10.1016/ j.healun.2013.01.321.

14. Schmitto JD, Molitoris U, Haverich A et al. Implantation of a centrifugal pump as a left ventricular assist device through a novel, minimized approach: Upper hemisternotomy combined with anterolateral thoracotomy. J Thorac Cardiovasc Surg 2012; 143: 511– 513. doi: 10.1016/ j.jtcvs.2011.07.046.

15. Berglund E, Sarnoff SJ, Isaacs JP. Ventricular Function Role of the Pericardium in Regulation of Cardiovascular Hemodynamics. Circ Res 1955; 3: 133– 139. doi: 10.1161/ 01.RES.3.2.133.

16. Feldman D, Pamboukian SV, Teuteberg JJ et al. The 2013 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: executive summary. J Heart Lung Transplant 2013; 32: 157– 187. doi: 10.1016/ j.healun.2012.09.013.

17. McKenna DH Jr, Eastlund T, Segall M et al. HLA alloimmunization in patients requiring ventricular assist device support. J Heart Lung Transplant 2002; 21: 1218– 1224. doi: 10.1016/ S1053– 2498(02)00448– 5.

18. Pagani FD, Dyke DB, Wright S et al. Development of anti‑major histocompatibility complex class I or II antibodies following left ventricular assist device implantation: effects on subsequent allograft rejection and survival. J Heart Lung Transplant 2001; 20: 646– 653.

19. Bull DA, Reid BB, Selzman CH at al. The impact of bridge‑ to‑ transplant ventricular assist device support on survival after cardiac transplantation. J Thorac Cardiovasc Surg 2010; 140: 169– 173. doi: 10.1016/ j.jtcvs.2010.03.026.

20. Borel JF. Comparative study of in vitro and in vivo drug effects on cell‑ mediated cytotoxicity. Immunology 1976; 31: 631– 641.

21. Adam Z, Krejčí J, Krejčí M et al. Heart transplantation and the subsequent treatment of AL amyloidosis Vnitr Lek 2013; 59: 136– 147.

22. Koordinační středisko transplantací: Zákony a vyhlášky 2014. Dostupné z: http:/ / www.kst.cz/ web/ download/ zakon_285– 2013– 5.pdf.

23. Kilic A, Weiss ES, George TJ et al. What Predicts Long‑Term Survival After Heart Transplantation? An Analysis of 9,400 Ten‑ Year Survivors. Ann Thorac Surg 2012, 93: 699– 704. doi: 10.1016/ j.athoracsur.2011.09.037.

24. Khush KK, Menza R, Nguyen J et al. Donor predictors of allograft use and recipient outcomes after heart transplantation. Circ Heart Fail 2013; 6: 300– 309. doi: 10.1161/ CIRCHEARTFAILURE.112.000165.

25. Sarsam MA, Campbell CS, Yonan NA et al. An alternative surgical technique in orthotopic cardiac transplantation. J Card Surg 1993; 8: 344– 349. doi: 10.1111/ j.1540– 8191.1993.tb00375.x.

26. Billingham ME, Cary NR, Hammond ME et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. The International Society for Heart Transplantation. J Heart Transplant 1990; 9: 587– 593.

27. Stewart S, Winters GL, Fishbein MC et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710– 1720. doi: 10.1016/ j.healun.2005.03.019.

28. Patel JK, Kobashigawa JA. Should we be doing routine biopsy after heart translantation in a new era of antirejection? Curr Opin Cardiol 2006; 21: 127– 131. doi: 10.1097/ 01.hco.0000210309.71984.30

29. Pirk J, Málek I. Transplantace srdce. 1st ed. Praha: Karolinum 2008: 129– 130.